Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 4 of 14

11. GH Research PLC (NASDAQ:GHRS)

Number of Hedge Fund Holders In Q4 2024: 10

GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel and proprietary mebufotenin (5-MeO-DMT) therapies for conditions like treatment-resistant depression.

The stock is up significantly so far in 2025 after the announcement of positive Phase 2b clinical trial results for their lead product candidate GH001 in treatment-resistant depression (TRD).

It showed a significant placebo-adjusted MADRS reduction of -15.5 on Day 8 and an impressive 57.5% remission rate compared to 0% in the placebo group. 78% of participants sustained remission.

The consensus price target of $30.6 implies 187.32% upside.

GHRS is up 52.14% year-to-date.

Page 4 of 14